Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts.
about
Hypericin in the Light and in the Dark: Two Sides of the Same CoinTumor resistance to vascular disrupting agents: mechanisms, imaging, and solutionsRadioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation.Necrosis targeted combinational theragnostic approach using radioiodinated Sennidin A in rodent tumor models.An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors.Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models.Tumor necrosis targeted radiotherapy of non-small cell lung cancer using radioiodinated protohypericin in a mouse model.Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications.Solid Tumor Therapy Using a Cannon and Pawn Combination Strategy.Improved therapeutic outcomes of thermal ablation on rat orthotopic liver allograft sarcoma models by radioiodinated hypericin induced necrosis targeted radiotherapy.Necrosis avidity: a newly discovered feature of hypericin and its preclinical applications in necrosis imagingCombretastatin A4-phosphate and its potential in veterinary oncology: a review.Effects of skeleton structure on necrosis targeting and clearance properties of radioiodinated dianthrones.Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models.Excretion and toxicity evaluation of 131I-Sennoside A as a necrosis-avid agent.Radiopharmaceutical evaluation of (131)I-protohypericin as a necrosis avid compound.Improved clearance of radioiodinated hypericin as a targeted anticancer agent by using a duodenal drainage catheter in rats.Biodistribution and tolerance of intravenous iodine-131-labelled hypericin in healthy dogs.Hypericin as a marker for determination of myocardial viability in a rat model of myocardial infarction.Evaluation of a metalloporphyrin (THPPMnCl) for necrosis-affinity in rat models of necrosis.Experimental evaluation of radioiodinated sennoside B as a necrosis-avid tracer agent.Radiopharmaceutical study on Iodine-131-labelled hypericin in a canine model of hepatic RFA-induced coagulative necrosis.Improvement of solubility and targetability of radioiodinated hypericin by using sodium cholate based solvent in rat models of necrosis.
P2860
Q26747362-8EE0E409-64C2-4F43-9053-524006EC4F59Q26774355-9BBA2E97-5BE3-4D53-9F6B-85B636FAF581Q30660860-AC01D0FB-E521-4692-AFED-242006E27924Q33917524-254E074F-7492-4C93-A9B4-E2C218B9E889Q34093032-EC476C8C-9AC1-467C-B74B-8B5DB1FDFCFDQ35077659-9DC9F189-779F-462C-AA78-DF5C4FB0DBF1Q35987317-68E5FD34-2F58-4706-9736-71D564366256Q36413470-1F03C9BC-238D-4D10-BD19-F76CDBBFFB79Q36609881-D6C5E9E7-3582-4D73-85E7-10B8F3F7F201Q36926018-7CE93BDC-2C45-4FFD-94B4-54B6214355CDQ37588304-BA26E648-5EE7-4FD3-AF05-E8EDE7C6C8F2Q38139930-CA1FD76C-0445-43A5-AEE3-550C53437D7CQ38490875-29B85DCF-5C0A-4FCF-B93A-8AB87D19224AQ38818263-D93B82EE-E9E6-4550-A959-B441F662AA94Q38921976-166DB2AC-8B3D-42C0-9F81-62070C89D2A9Q39199545-3D7689D2-C407-4188-844E-0C9738DF61CFQ41473512-0DD1DF57-07BD-4E42-85D2-F49F8AB11D7BQ46089452-D9FA0532-E8A9-44B5-83EC-B07E954C08BEQ48286237-4AE13FE8-55CE-4359-B28C-4783CFB96215Q50480363-35E55624-6074-4E00-BA67-D931B177E511Q52659819-9E8689C0-3100-4A8B-8EB6-26CC0DCD7A5AQ53044553-DE0B03BF-45D4-4FEA-B316-B6B7ECE2E41DQ53060211-26BD548F-CFF4-4AC7-B407-94E92C6D5A27Q53086010-29DA6AF5-8B8E-4086-9D13-3076D657B8B0
P2860
Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Sequential systemic administra ...... ying bifocal tumor xenografts.
@ast
Sequential systemic administra ...... ying bifocal tumor xenografts.
@en
type
label
Sequential systemic administra ...... ying bifocal tumor xenografts.
@ast
Sequential systemic administra ...... ying bifocal tumor xenografts.
@en
prefLabel
Sequential systemic administra ...... ying bifocal tumor xenografts.
@ast
Sequential systemic administra ...... ying bifocal tumor xenografts.
@en
P2093
P2860
P356
P1433
P1476
Sequential systemic administra ...... ying bifocal tumor xenografts.
@en
P2093
Alfons Verbruggen
Guozhi Zhang
Jian Zhang
Marlein Miranda Cona
Raymond Oyen
Yicheng Ni
P2860
P304
P356
10.7150/THNO.5790
P577
2013-02-13T00:00:00Z